Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

Recurrent Urinary Tract Infection Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Use of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04306731
• Other study ID #: College of Medicine
• Status: Completed
• Phase: N/A
• Start date: September 20, 2014
• Est. completion date: April 21, 2017

Study information

• Verified date: March 2020
• Source: University of Sulaimani
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigates nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females.

Description:

This study represents the first time to use nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females. Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months.

Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and the side effects of antibiotics have led to the search for an alternative non-antibiotic prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water that has been prepared using different types of energy fields and electromagnetic fields to produce this structured water, which has new and different characteristics from the ordinary water.

In the current study, the efficacy of nanotechnology structured water magnalife was compared with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 437
• Est. completion date: April 21, 2017
• Est. primary completion date: April 21, 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 24 Years to 80 Years

Eligibility

Inclusion Criteria:

• = 2 (two or more than two) UTI in the last 6 months

• = 3 (three or more than three) UTI in the last 12 months

Exclusion Criteria:

• immunotherapy

• radiotherapy

• malignancy

• steroids

• chronic infections

• chemotherapy

• immunosuppressive drugs

• anatomical abnormality of the urinary tract

• surgical operation the urinary tract

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Recurrent Urinary Tract Infection
• Urinary Tract Infections

Intervention

Dietary Supplement:
• Nanotechnology Structured water Magnalife
Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules

Drug:
• Trimethoprim
Antibiotic

Dietary Supplement:
• Ordinary bottled drinking water
Placebo

Locations

Country	Name	City	State
Iraq	College of Medicine, University of Sulaimani	Sulaymaniyah	Kurdistan Region

Sponsors (1)

Lead Sponsor	Collaborator
University of Sulaimani

Country where clinical trial is conducted

Iraq, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrent Urinary Tract Infection	Urinalysis by GUE (>10 white blood cells (WBC)/mm3 per high-power field (HPF) Urine culture (urinary pathogen of =105 colony-forming units (CFU) per mL)	Twelve months
Secondary	Time to first recurrent UTI	The time since the beginning of the study until the first recurrent UTI (days)	Twelve months